company background image
MITRA

Mithra Pharmaceuticals ENXTBR:MITRA Stock Report

Last Price

€4.18

Market Cap

€225.2m

7D

-8.5%

1Y

-79.4%

Updated

05 Dec, 2022

Data

Company Financials +
MITRA fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health0/6
Dividends0/6

MITRA Stock Overview

Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Europe and internationally.

Mithra Pharmaceuticals SA Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Mithra Pharmaceuticals
Historical stock prices
Current Share Price€4.18
52 Week High€22.10
52 Week Low€4.16
Beta0.96
1 Month Change-33.76%
3 Month Change-39.94%
1 Year Change-79.36%
3 Year Change-84.36%
5 Year Change-60.90%
Change since IPO-65.02%

Recent News & Updates

Bullish: Analysts Just Made A Huge Upgrade To Their Mithra Pharmaceuticals SA (EBR:MITRA) Forecasts

Aug 11
Bullish: Analysts Just Made A Huge Upgrade To Their Mithra Pharmaceuticals SA (EBR:MITRA) Forecasts

Recent updates

Bullish: Analysts Just Made A Huge Upgrade To Their Mithra Pharmaceuticals SA (EBR:MITRA) Forecasts

Aug 11
Bullish: Analysts Just Made A Huge Upgrade To Their Mithra Pharmaceuticals SA (EBR:MITRA) Forecasts

Growth Investors: Industry Analysts Just Upgraded Their Mithra Pharmaceuticals SA (EBR:MITRA) Revenue Forecasts By 21%

Mar 13
Growth Investors: Industry Analysts Just Upgraded Their Mithra Pharmaceuticals SA (EBR:MITRA) Revenue Forecasts By 21%

Mithra Pharmaceuticals (EBR:MITRA) Is Making Moderate Use Of Debt

Dec 22
Mithra Pharmaceuticals (EBR:MITRA) Is Making Moderate Use Of Debt

Some Mithra Pharmaceuticals SA (EBR:MITRA) Analysts Just Made A Major Cut To Next Year's Estimates

Nov 24
Some Mithra Pharmaceuticals SA (EBR:MITRA) Analysts Just Made A Major Cut To Next Year's Estimates

Here's Why Mithra Pharmaceuticals (EBR:MITRA) Can Afford Some Debt

Jun 07
Here's Why Mithra Pharmaceuticals (EBR:MITRA) Can Afford Some Debt

When Will Mithra Pharmaceuticals SA (EBR:MITRA) Turn A Profit?

May 10
When Will Mithra Pharmaceuticals SA (EBR:MITRA) Turn A Profit?

Is Mithra Pharmaceuticals SA's (EBR:MITRA) Shareholder Ownership Skewed Towards Insiders?

Mar 18
Is Mithra Pharmaceuticals SA's (EBR:MITRA) Shareholder Ownership Skewed Towards Insiders?

We're Not So Sure You Should Rely on Mithra Pharmaceuticals' (EBR:MITRA) Statutory Earnings

Feb 16
We're Not So Sure You Should Rely on Mithra Pharmaceuticals' (EBR:MITRA) Statutory Earnings

Analysts Expect Breakeven For Mithra Pharmaceuticals SA (EBR:MITRA) Before Long

Jan 21
Analysts Expect Breakeven For Mithra Pharmaceuticals SA (EBR:MITRA) Before Long

Some Mithra Pharmaceuticals SA (EBR:MITRA) Analysts Just Made A Major Cut To Next Year's Estimates

Nov 29
Some Mithra Pharmaceuticals SA (EBR:MITRA) Analysts Just Made A Major Cut To Next Year's Estimates

Shareholder Returns

MITRABE PharmaceuticalsBE Market
7D-8.5%1.2%0.9%
1Y-79.4%2.9%-7.4%

Return vs Industry: MITRA underperformed the Belgian Pharmaceuticals industry which returned 3.7% over the past year.

Return vs Market: MITRA underperformed the Belgian Market which returned -5.1% over the past year.

Price Volatility

Is MITRA's price volatile compared to industry and market?
MITRA volatility
MITRA Average Weekly Movement8.0%
Pharmaceuticals Industry Average Movement5.4%
Market Average Movement4.8%
10% most volatile stocks in BE Market7.1%
10% least volatile stocks in BE Market3.0%

Stable Share Price: MITRA is more volatile than 90% of Belgian stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: MITRA's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of Belgian stocks.

About the Company

FoundedEmployeesCEOWebsite
1999300Leon Van Rompayhttps://www.mithra.com

Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Europe and internationally. Its development candidates include Estelle, which has completed phase III clinical trial, which is a combined oral contraceptive; Donesta, which is in phase III clinical trial for estetrol-based oral hormone treatment. The company also develops Myring, a contraceptive vaginal ring releasing a combination of hormones; Tibelia, a solution for treating menopause and osteoporosis; and Zoreline, a biodegradable subcutaneous implant for use in prostate and breast cancers, and benign gynecological indications.

Mithra Pharmaceuticals SA Fundamentals Summary

How do Mithra Pharmaceuticals's earnings and revenue compare to its market cap?
MITRA fundamental statistics
Market Cap€225.18m
Earnings (TTM)-€93.23m
Revenue (TTM)€21.88m

10.3x

P/S Ratio

-2.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
MITRA income statement (TTM)
Revenue€21.88m
Cost of Revenue€14.56m
Gross Profit€7.32m
Other Expenses€100.55m
Earnings-€93.23m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.73
Gross Margin33.46%
Net Profit Margin-426.03%
Debt/Equity Ratio834.3%

How did MITRA perform over the long term?

See historical performance and comparison